company background image
PEHA

Phapros IDX:PEHA Stock Report

Last Price

Rp1.01k

Market Cap

Rp848.4b

7D

0.5%

1Y

-15.5%

Updated

22 May, 2022

Data

Company Financials
PEHA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance1/6
Financial Health3/6
Dividends2/6

PEHA Stock Overview

PT Phapros, Tbk operates in the pharmaceutical and health care industry in Indonesia.

Phapros Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Phapros
Historical stock prices
Current Share PriceRp1,010.00
52 Week HighRp1,550.00
52 Week LowRp990.00
Beta0.34
1 Month Change1.00%
3 Month Change-11.40%
1 Year Change-15.48%
3 Year Change-45.41%
5 Year Changen/a
Change since IPO-43.89%

Recent News & Updates

Shareholder Returns

PEHAID PharmaceuticalsID Market
7D0.5%1.7%3.3%
1Y-15.5%0.7%18.2%

Return vs Industry: PEHA underperformed the ID Pharmaceuticals industry which returned 0.7% over the past year.

Return vs Market: PEHA underperformed the ID Market which returned 18.2% over the past year.

Price Volatility

Is PEHA's price volatile compared to industry and market?
PEHA volatility
PEHA Average Weekly Movement1.7%
Pharmaceuticals Industry Average Movement3.7%
Market Average Movement6.2%
10% most volatile stocks in ID Market12.0%
10% least volatile stocks in ID Market3.0%

Stable Share Price: PEHA is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: PEHA's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19541,669Hadi Kardokohttps://www.phapros.co.id

PT Phapros, Tbk operates in the pharmaceutical and health care industry in Indonesia. The company operates through Over the Counter (OTC), Ethical, Generic Drugs Bearing, and Toll Manufacturing segments. It offers OTC drugs, including Antimo Anak, Livron B Plek, Noza, Hemorogard, Bioron, and others.

Phapros Fundamentals Summary

How do Phapros's earnings and revenue compare to its market cap?
PEHA fundamental statistics
Market CapRp848.40b
Earnings (TTM)Rp11.07b
Revenue (TTM)Rp1.05t

76.6x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PEHA income statement (TTM)
RevenueRp1.05t
Cost of RevenueRp549.38b
Gross ProfitRp502.07b
Other ExpensesRp491.00b
EarningsRp11.07b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)13.18
Gross Margin47.75%
Net Profit Margin1.05%
Debt/Equity Ratio115.8%

How did PEHA perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

175%

Payout Ratio

Valuation

Is Phapros undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


35.5%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: PEHA (IDR1010) is trading below our estimate of fair value (IDR1566.2)

Significantly Below Fair Value: PEHA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PEHA is poor value based on its PE Ratio (76.6x) compared to the ID Pharmaceuticals industry average (20.7x).

PE vs Market: PEHA is poor value based on its PE Ratio (76.6x) compared to the ID market (18.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PEHA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PEHA is good value based on its PB Ratio (1.2x) compared to the ID Pharmaceuticals industry average (2.5x).


Future Growth

How is Phapros forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Phapros has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Phapros performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-27.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PEHA has high quality earnings.

Growing Profit Margin: PEHA's current net profit margins (1.1%) are lower than last year (4.9%).


Past Earnings Growth Analysis

Earnings Trend: PEHA's earnings have declined by 27.2% per year over the past 5 years.

Accelerating Growth: PEHA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PEHA had negative earnings growth (-77.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (11.7%).


Return on Equity

High ROE: PEHA's Return on Equity (1.5%) is considered low.


Financial Health

How is Phapros's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: PEHA's short term assets (IDR949.1B) exceed its short term liabilities (IDR732.0B).

Long Term Liabilities: PEHA's short term assets (IDR949.1B) exceed its long term liabilities (IDR365.5B).


Debt to Equity History and Analysis

Debt Level: PEHA's net debt to equity ratio (103.1%) is considered high.

Reducing Debt: PEHA's debt to equity ratio has increased from 17.5% to 115.8% over the past 5 years.

Debt Coverage: PEHA's debt is well covered by operating cash flow (22.1%).

Interest Coverage: PEHA's interest payments on its debt are not well covered by EBIT (1.2x coverage).


Balance Sheet


Dividend

What is Phapros's current dividend yield, its reliability and sustainability?

Dividend Score

1/6

Dividend Score 1/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


2.29%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: PEHA's dividend (2.29%) is higher than the bottom 25% of dividend payers in the ID market (1.13%).

High Dividend: PEHA's dividend (2.29%) is low compared to the top 25% of dividend payers in the ID market (4.15%).


Stability and Growth of Payments

Stable Dividend: PEHA has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: PEHA has only been paying a dividend for 3 years, and since then payments have fallen.


Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (175.2%), PEHA's dividend payments are not well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (10.7%), PEHA's dividend payments are thoroughly covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Hadi Kardoko (45 yo)

1.92yrs

Tenure

Mr. Hadi Kardoko, S.Si., Apt has been President Director at PT Phapros, Tbk since June 2020. He served as General Manager of Manufacturing at PT Kimia Farma Tbk in 2018, as well as General Manager of Trans...


Leadership Team

Experienced Management: PEHA's management team is considered experienced (4.2 years average tenure).


Board Members

Experienced Board: PEHA's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PT Phapros, Tbk's employee growth, exchange listings and data sources


Key Information

  • Name: PT Phapros, Tbk
  • Ticker: PEHA
  • Exchange: IDX
  • Founded: 1954
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: Rp848.400b
  • Shares outstanding: 840.00m
  • Website: https://www.phapros.co.id

Number of Employees


Location

  • PT Phapros, Tbk
  • Rajawali Tower 17th Floor
  • 17th Floor
  • Jakarta
  • Jakarta Raya
  • 12950
  • Indonesia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/22 00:00
End of Day Share Price2022/05/20 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.